singapore biopharmaceutical company astrazeneca deliver antibody drug covid treatment singapore end year company ha signed new purchase agreement country deliver evusheld drug cocktail said news release friday dec evusheld combine two longacting antibody tixagevimab cilgavimab ha studied treatment prevention covid participant astrazeneca said phase trial drug showed per cent reduced risk severe covid death patient mildtomoderate covid treated within three day symptom onset added preliminary finding also shown effectiveness variant concern including delta drugmaker added currently available preclinical data also suggest evusheld efficacy significantly impacted new omicron variant astrazeneca said related us authorises astrazeneca covid treatment case astrazeneca antibody cocktail study show success treating covid response cnas query ministry health moh friday confirmed ha purchased evusheld treatment covid this part ongoing effort ensure range covid treatment option different patient groups said moh country president astrazeneca singapore mr vinod narayanan said evusheld provides healthcare professional patient singapore new option fight virus additionally evusheld provide another prevention option highrisk population alongside vaccine including people immunocompromised unable develop needed degree protective response following covid vaccination said earlier week company received emergency use authorization evusheld us food drug administration news release said astrazeneca said ha also filed regulatory approval country october msd known merck united states canada said entered supply purchase agreement singapore provide molnupiravir investigational antiviral drug treat covid authorised approved bookmark comprehensive coverage covid pandemic development download app subscribe telegram channel latest update coronavirus outbreak httpscnaasiatelegram